Compare TKNO & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | OABI |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.1M | 294.3M |
| IPO Year | 2021 | 2021 |
| Metric | TKNO | OABI |
|---|---|---|
| Price | $9.33 | $4.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 201.7K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | 6.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | $18,666,000.00 |
| Revenue This Year | $8.27 | $52.42 |
| Revenue Next Year | $13.13 | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $1.32 |
| 52 Week High | $9.41 | $5.43 |
| Indicator | TKNO | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 73.40 | 60.73 |
| Support Level | $4.87 | $1.90 |
| Resistance Level | N/A | $5.43 |
| Average True Range (ATR) | 0.47 | 0.25 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 80.13 | 72.40 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.